Searched for
ZETIA
Expect to reduce net debt by about Rs 300 crore: Glenn Saldanha, Glenmark PharmaceuticalsThere is a bunch of products approvals coming through for most of the Indian companies that do not have any outstanding compliance issues.- Sun Pharma receives USFDA nod for anti-cholesterol drug"As per IMS, ezetimibe tablets had annual sales of approximately USD 2.7 billion in the US for the 12 months ended April 2017," it added.
- Nifty Pharma trading up, Sun Pharma top gainerAmong the 51 stocks in Nifty index, 37 were trading in green, while 14 were in red.
- Sensex rises over 100 points; Nifty above 9,600; Sun Pharma, UltraTech top gainersAfter opening on a flat note, the BSE Sensex was trading 100 points up at 31,195.
- Glenmark’s attractive post fall on strong business, R&DIn the long term, the company expects its focus on R&D to show results.
- Launch of gZetia positively impacted US business: Glenn Saldanha, GlenmarkIn an exclusive interview to ET Now, Glenn Saldanha, CMD, Glenmark, said next few quarters will be strong due to gZetia.
- Glenmark Pharma surges 7% as brokerages stay upbeat post Q3 numbersBofa-ML believes that the growth momentum in the US geography is likely to sustain beyond 6-month exclusivity for cholesterol lowering drug...
- Neutral Glenmark Pharmaceuticals with a target of Rs 960: UBSExpect base US biz to improve as a result of recent launches in dermatology. UBS has forecast a 33% EPS CAGR over FY16-18E for Glenmark Pha...
- Glenmark launches generic version of Zetia in US market"We have launched ezetimibe, the first and only generic version of Zetia (Merck) in the United States for the treatment of high cholesterol...
- Glenmark Pharma shares jump 6% on debt reduction planFollowing the development, the stock rose 5.9 per cent to hit a high of Rs 993 on BSE. This is nearly 10 per cent higher than October 27’s ...
- Caution is the buzzword on Dalal Street: Ajay Bodke, Prabhudas LilladherGlenmark Pharma and Hexaware Technologies are the two high conviction investment ideas
- Underperform on Glenmark with a target at Rs 900: CLSAWeak free cash flows (FCF) a concern while balance sheet improvement only in 1HFY18. Going forward, improvement hinges on successful Zetia ...
- US Food and Drug Administration approves drug to cut cholesterolMorgan Liscinsky, an FDA spokeswoman, said high levels of LDL cholesterol were a known risk factor for heart disease.
- Stocks to watch: Tata Power, Fortis Healthcare, Jindal Steel, MMTC, Jubilant Foodworks, GlenmarkTata Power said it was not inclined to accept an order from the Maharashtra govt asking it to supply around 300 MW to RInfra, setting the s...
- Merck Q1 sales rise but profit fall on chargesDrugmaker Merck & Co. says double-digit sales growth for a half-dozen of its top medicines fueled a 7 percent jump in first-quarter sales.
- Glenmark in licensing deal with US co for cholesterol drugDrug firm Glenmark on Tuesday said it has signed an exclusive licensing agreement with the US-based Par Pharmaceutical to sell generic chol...
- US court to hear Glenmark's patent dispute on Aug 19Glenmark Pharmaceuticals’ patent challenge against Schering Plough’s cholesterol-lowering drug Zetia will come up for hearing in the US dis...
- Glenmark gets first nod for Zetia genericGlenmark Pharmaceuticals has got tentative approval from the USFDA for the generic version of Schering Plough and MSP Singapore Company LLC...
- Glenmark Pharma consolidated net up 254% in ’06-07Buoyed by a revenue growth in the US market, Glenmark Pharmaceuticals has posted a 253.6% jump in consolidated net profit to Rs 311.1 crore...
- Cholesterol drugmakers brace for competitionThe makers of cholesterol drugs are promoting their products ahead of a major change that is expected to trigger more competition in the ma...
Load More
